Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P14 - Immunotherapy (Phase II/III Trials) - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P14.01 - Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC
00:00 - 00:00 | Presenter: Matthew D. Hellmann
- Abstract
Loading...
-
+
P50 - Novel Therapeutics and Targeted Therapies - EGFR Minor
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P50.04 - Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Misako Nagasaka
- Abstract
Loading... -
+
P50.09 - Characteristics and Clinical Outcomes of HER2 Mutated Non-small Cell Lung Cancer Patients Detected by NGS in Routine Clinical Practice
00:00 - 00:00 | Presenter: Yejeong Han
- Abstract
Loading...
-
+
P59 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Targeted Therapies Biomarkers
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
P59.01 - Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy
00:00 - 00:00 | Presenter: Ji Hyun Lee
- Abstract
Loading...
-
+
PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 06:30 - 08:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
06:30 - 06:40 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)
- 14:30 - 16:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02A.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
14:30 - 14:40 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
ES04 - Antibody–Drug Conjugates: Current Status and Future Perspectives*
- 09:00 - 09:35
- 9/10/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Education Session
- Track: Novel Therapeutics and Targeted Therapies
*Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.- Moderators:Maria Rosario García Campelo, Ana Gelatti
-
+
ES04.04 - Antibody Drug Conjugates for Combination Therapy
09:06 - 09:08 | Presenter: Byoung Chul Cho
- Abstract
No abstract available for this presentation
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
19:05 - 19:15 | Presenter: Alexander Spira
- Abstract
Loading...
